Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD) — StellaPhase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.
Trial locations(20 sites)
United States
Cedars-Sinai Department of Neurology, Los Angeles, California University of California San Francisco, San Francisco, California Parkinson's Disease and Movement Disorders Center, Boca Raton, Florida Beth Israel Deaconess Medical Center, Boston, Massachusetts Ichan School of Medicine at Mount Sinai/Beth Israel Downtown-Movement Disorder Center, New York, New York Last updated February 2026